Cathepsin S as a Biomarker in Non-Hodgkin's Lymphoma
Author Information
Author(s): Bosa Mirjanić-Azarić, Siniša Stanković, Zana Radić-Savić, Dragana Malčić-Zanić, Ana Ninić, Marija Vuković, Lana Nezić, Ranko Skrbić, Nataša Bogavac-Stanojević
Primary Institution: University of Banja Luka, Faculty of Medicine
Hypothesis
Can cathepsin S serve as a potential biomarker for non-Hodgkin's lymphoma?
Conclusion
Cathepsin S levels are significantly elevated in patients with non-Hodgkin's lymphoma, indicating its potential as a diagnostic biomarker.
Supporting Evidence
- CTSS levels were significantly higher in NHL patients than in control subjects.
- There was a positive correlation between CTSS and HDL subclasses in NHL patients.
- The area under the ROC curve for CTSS was 0.766, indicating moderate diagnostic value.
Takeaway
This study found that a protein called cathepsin S is higher in people with a type of cancer called non-Hodgkin's lymphoma, which might help doctors diagnose it better.
Methodology
The study included 90 subjects, including lymphoma patients and healthy controls, with serum cathepsin S measured using an ELISA kit.
Limitations
The study had a relatively small number of patients and was affected by COVID-19 restrictions, limiting follow-up assessments.
Participant Demographics
The study included 90 subjects: 11 Hodgkin lymphoma patients, 44 B-cell non-Hodgkin lymphoma patients, and 35 healthy subjects.
Statistical Information
P-Value
p<0.001
Confidence Interval
CI: 0.655-0.856
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website